April -
- Total revenue
SEK 3,876 M (3,211), +21 per cent, +10 per cent at constant exchange rates (CER)1 - Haematology revenue
SEK 2,688 M (2,125), +16 per cent at CER of which Elocta®SEK 1,107 M (1,005), +6 per cent at CER; Alprolix®SEK 468 M (438), +2 per cent at CER; Doptelet®SEK 618 M (230), +126 per cent at CER and Aspaveli®/Empaveli™SEK 38 M (-) - Immunology revenue
SEK 847 M (752), stable at CER of which Kineret®SEK 545 M (550), -11 per cent at CER; Synagis®SEK 39 M (33), +10 per cent at CER and Gamifant®SEK 263 M (168), +34 per cent at CER - EBITA
1 SEK 944 M (922); EBITA margin1 24 percent (29) . Items affecting comparability2 (IAC) ofSEK -14 M included a reversal of a provision for Russian receivables ofSEK 51 M. Excluding IAC, EBITA adjusted1 wasSEK 958 M corresponding to an EBITA margin adjusted1 of 25 percent (29) . EBITSEK 423 M (467), EBIT adjusted1 SEK 437 M (467) - Earnings per share (EPS) before dilution
SEK 0.87 (0.91); EPS before dilution adjustedSEK 0.91 (0.91). Cash flow from operating activitiesSEK 343 M (1,393)
- Significant events after the reporting period: efanesoctocog alfa phase 3 data presentation; agreement to license the new orphan medicine loncastuximab tesirine in haematology
January -
- Total revenue
SEK 8,801 M (6,872), +28 per cent, +17 per cent at CER1 - Haematology revenue
SEK 5,187 M (4,003), +20 per cent at CER of which EloctaSEK 2,132 M (1,861), +10 per cent at CER; AlprolixSEK 887 M (851), stable at CER; DopteletSEK 1,211 M (411), +155 per cent at CER and Aspaveli/EmpaveliSEK 42 M (-) - Immunology revenue
SEK 2,967 M (2,305), +15 per cent at CER of which KineretSEK 1,190 M (1,092), stable at CER; SynagisSEK 1,325 M (912), +29 per cent at CER and GamifantSEK 452 M (301), +30 per cent at CER - EBITA
1 SEK 2,234 M (2,406); EBITA margin1 25 percent (35) . IAC2 ofSEK -675 M, excluding IAC, EBITA adjusted1 wasSEK 2,909 M corresponding to an EBITA margin adjusted1 of 33 percent (35) . EBITSEK 1,198 M (1,500); EBIT adjusted1 SEK 1,873 M (1,500)
- EPS before dilution
SEK 2.71 (3.27), EPS before dilution adjustedSEK 4.56 (3.27). Cash flow from operating activitiesSEK 1,987 M (3,092)
2022 outlook
- Revenue is anticipated to grow by a mid to high single-digit percentage at CER, now potentially towards the higher end of the range
· EBITA margin adjusted is anticipated to be at a low 30s percentage of revenue, now including the cost effects of the agreement to license the new orphan medicine loncastuximab tesirine in haematology
Financial summary
Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.
To participate in the conference call, please call:
US: +1 646 722 4957
Sobi®
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the
Head of Communication and Investor Relations
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q2-2022-report,c3602893
https://mb.cision.com/Main/14266/3602893/1605593.pdf
https://news.cision.com/swedish-orphan-biovitrum-ab/i/3602893-0-png,c3071439
(c) 2022 Cision. All rights reserved., source